anti-Fas (human), mAb (APO-1-1) (preservative free)
| Code | Size | Price |
|---|
| AG-20B-0079PF-C100 | 100 ug | £165.00 |
Quantity:
| AG-20B-0079PF-C500 | 500 ug | £560.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Antibody Clonality: Monoclonal
Regulatory Status: RUO
Shipping:
Blue Ice
Storage:
+4°C
Documents
Further Information
Alternate Names/Synonyms:
CD95; APO-1; TNFRSF6; Tumor Necrosis Factor Receptor Superfamily Member 6; Apoptosis-mediating Surface Antigen FAS
Concentration:
1 mg/ml.
EClass:
32160000
Form (Short):
liquid
Formulation:
Liquid. In PBS.
Handling Advice:
Avoid freeze/thaw cycles.
Immunogen:
Recombinant human Fas.
Labels - Conjugates:
Preservative Free
Long Description:
Monoclonal antibody. Recognizes human Fas. Applications: FACS, FUNC, IHC. Clone: APO-1-1. Isotype: Mouse IgG1. Liquid. In PBS. Purity: >95% (SDS-PAGE). Fas (CD95) is a member of the death receptor (DR) family, a subfamily of the tumor necrosis factor receptor superfamily. The formation of the Fas death-inducing signaling complex (DISC) is the initial step of Fas signaling. Activation of procaspase-8 at the DISC leads to the induction of DR-mediated apoptosis. Stimulation of Fas has also been reported to trigger non-apoptotic pathways. It has been shown that membrane-bound FasL is essential for the cytotoxic activity, whereas soluble FasL appears to promote autoimmunity and tumorigenesis via induction of non-apoptotic pathways, in particular NF-kappaB.
NCBI, Uniprot Number:
P25445
Package Type:
Plastic Vial
Product Description:
Fas (CD95) is a member of the death receptor (DR) family, a subfamily of the tumor necrosis factor receptor superfamily. The formation of the Fas death-inducing signaling complex (DISC) is the initial step of Fas signaling. Activation of procaspase-8 at the DISC leads to the induction of DR-mediated apoptosis. Stimulation of Fas has also been reported to trigger non-apoptotic pathways. It has been shown that membrane-bound FasL is essential for the cytotoxic activity, whereas soluble FasL appears to promote autoimmunity and tumorigenesis via induction of non-apoptotic pathways, in particular NF-kappaB.
Purity:
>95% (SDS-PAGE)
Source / Host:
Purified from concentrated hybridoma tissue culture supernatant.
Specificity:
Recognizes human Fas.
Transportation:
Non-hazardous
UNSPSC Category:
Primary Antibodies
UNSPSC Number:
12352203
Use & Stability:
Stable for at least 1 year after receipt when stored at -20°C.
References
Monoclonal antibody-mediated tumor regression by induction of apoptosis: B.C. Trauth, et al.; Science 245, 301 (1989) | Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens: J. Dhein, et al.; J. Immunol. 149, 3166 (1992) | Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells: F. Leithauser, et al.; Lab. Invest. 69, 415 (1993) (IHC Application) | Ligand-independent redistribution of Fas (CD95) into lipid rafts mediates clonotypic T cell death: J.R. Muppidi & R.M. Siegel; Nat. Immunol. 5, 182 (2004) | Role of CD95-mediated adipocyte loss in autoimmune lipodystrophy: P. Fischer-Posovszky, et al.; J. Clin. Endocrinol. Metab. 91, 1129 (2006) | Cutting edge: Rac GTPases sensitize activated T cells to die via Fas: M. Ramaswamy, et al.; J. Immunol. 179, 6384 (2007) | Low FAS/CD95 Expression by CTCL Correlates withReduced Sensitivity to Apoptosis that Can BeRestored by FAS Upregulation: J. Wu, et al.; J. Invest. Dermatol. 129, 1165 (2009) (IHC Application) | Natural killer cells induce distinct modes of cancer cell death: Discrimination, quantification and modulation of apoptosis, necrosis and mixed forms: C.S. Backes, et al.; J. Biol. Chem. 293, 16348 (2018) | Epigenetically Enhanced PDT Induces Significantly Higher Levels of Multiple Extrinsic Pathway Apoptotic Factors than Standard PDT, Resulting in Greater Extrinsic and Overall Apoptosis of Cutaneous T-cell Lymphoma: K.A. Salva, et al.; Photochem. Photobiol. 94, 1058 (2018) (IHC Application)